MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$4,182K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts receivable, net
Net proceeds received from revol...
Derivative warrant liabilities l...
Others
Negative Cash Flow Breakdown
Accrued liabilities
Prepaid expenses and other curre...
Accounts payable
Payments made to borrowings
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net (loss) income
-5,618
-10,584
1,965
-13,562
Depreciation and amortization
1,121
885
803
5,377
Impairment expense
-
-
-
8,263
Stock-based compensation expense
148
283
114
576
Derivative warrant liabilities loss (gain)
-1,257
-8,244
3,784
-1,703
Amortization of debt discount and issuance costs
27
29
29
108
Inventory write-down
653
835
278
325
Non-cash loss on extinguishment of debt
-
-
-
0
Other non-cash adjustments
-44
0
0
-752
Non-cash adjustments from discontinued operations
0
0
0
254
Accounts receivable, net
-6,434
-2,302
2,070
7,629
Inventories
-543
-609
-1,056
-382
Prepaid expenses and other current assets
2,025
1,483
-484
451
Accounts payable
-1,045
-1,083
1,741
287
Accrued liabilities
-5,886
3,456
-1,637
886
Other operating assets and liabilities, net
-165
-182
-403
-528
Changes in operating assets and liabilities from discontinued operations
0
0
0
-264
Net cash used in operating activities
-4,182
3,675
-618
-1,937
Cash received from sales of fixed assets
0
0
0
668
Cash payments for fixed asset purchases
0
17
0
228
Cash payments for acquired intangible assets
-
-
-
3,000
Net cash (used in) provided by investing activities
0
-17
0
-2,560
Net proceeds from issuance of common stock and warrants
-
-
-
14,840
Net proceeds received from revolving credit facility
1,336
-5,798
5,810
6,668
Payment made to fixed payment arrangements
0
0
3,050
6,016
Payments made to borrowings
464
465
464
1,857
Proceeds from borrowings
-
-
-
1,857
Payments for debt issuance costs
-
-
-
49
Net cash (used in) provided by financing activities
872
-6,263
2,296
15,443
Net change in cash and cash equivalents
-3,310
-2,605
1,678
10,946
Cash and cash equivalents at beginning of period
32,630
32,630
30,952
20,006
Cash and cash equivalents at end of period
26,715
30,025
32,630
30,952
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds
received from revolving...
$1,336K
Net cash (used in)
provided by financing...
$872K
Canceled cashflow
$464K
Net change in cash
and cash...
-$3,310K
Canceled cashflow
$872K
Accounts receivable, net
-$6,434K
Derivative warrant
liabilities loss (gain)
-$1,257K
Depreciation and
amortization
$1,121K
Inventory write-down
$653K
Inventories
-$543K
Other operating
assets and...
-$165K
Stock-based compensation
expense
$148K
Other non-cash
adjustments
-$44K
Amortization of debt discount
and issuance costs
$27K
Payments made to
borrowings
$464K
Net cash used in
operating activities
-$4,182K
Canceled cashflow
$10,392K
Accrued liabilities
-$5,886K
Net (loss) income
-$5,618K
Prepaid expenses and
other current assets
$2,025K
Accounts payable
-$1,045K
Buy us a coffee
AYTU BIOPHARMA, INC (AYTU)
AYTU BIOPHARMA, INC (AYTU)